护城河对比
最多三家已覆盖的公司，逐项对照。每一项判断都是人工编辑的判断，而非公司披露的数字——并且每一项都附有其引用依据。
| Nebius Group | Tencent Holdings | Pfizer | |
|---|---|---|---|
| 护城河评级 | 窄 The FY2025 20-F positions Nebius as 'one of the few global, at scale, multi-tenant clouds purpose built for AI,' but the same filing names its central dependency plainly: 'We currently rely on Nvidia for the GPU chips we use' — a purpose-built neocloud renting a supply the hyperscalers it competes with also control, which is a real but narrow position. | 宽 The 2025 Annual Report reports combined MAU of Weixin and WeChat of 1,418 million at 31 December 2025, still growing 2% year-on-year and 0.3% quarter-on-quarter off a 1.4-billion-account base, while group gross margin rose to 56% from 53% and Marketing Services revenue grew 19% to RMB145.0 billion 'primarily driven by growth in pricing and ad impressions'. Rising price on a still-growing user base of that size is the signature of a wide moat, not a contested one. | 正在侵蚀 The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| 护城河类型 | 成本规模 The moat the filing describes is engineering: designs that 'optimize power and cooling efficiency, lower latency' plus 'a consistent track record of being one of the first-to-deploy the latest generation of NVIDIA GPU chips' — density and time-to-deploy at scale, not a switching lock. | 网络效应 The report attributes Marketing Services pricing growth to 'an increasing proportion of closed-loop ads (where the user clicks through to native transactional experiences, such as Mini Programs, Mini Shops, or Mini Games)' and describes growing engagement with Mini Shops, Mini Games and content Mini Programs 'by strengthening Weixin's commerce experience and content ecosystem' - merchants and developers building inside the user graph rather than beside it, which is a network effect rather than a switching cost or a scale cost advantage. | 无形资产与知识产权 The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| 领先地位 | 快速追随者 The 20-F's own claim is 'one of the FEW global, at scale' AI clouds — a differentiated challenger to the hyperscalers it names as the competitive field, not a claimed leader of it; the first-to-deploy record is a follower's speed advantage, not category leadership. | 明确领先者 The only explicit leadership claims in the report are the Company's own: Tencent Video 'maintained its leading position in China's long-form video market' and Tencent Music 'extended its leading position in China's music streaming market'. Against a 1,418 million combined Weixin/WeChat MAU base, the report asserts leadership in the adjacent content markets and no competitor is named anywhere in it. | 并列领先者 The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| 定价权 | 弱 The filing frames a 'highly competitive' market with 'frequent introduction of new or improved solutions' and a GPU cost base set by a single supplier (NVIDIA) — a renter of compute competing on efficiency has little list-price control. | 强 Group gross margin was 56% for 2025, up from 53%, with segment gross margins of 60% for VAS (from 57%), 58% for Marketing Services (from 55%) and 51% for FinTech and Business Services (from 47%); Marketing Services revenue growth is attributed 'primarily' to pricing, and the Chairman's Statement notes ad load 'remained at a much lower level than peers'' - price is rising with monetisation headroom still unused. | 弱 Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| 综述 | Nebius sells a 'unified full-stack AI cloud that spans the complete AI journey – from compute capacity to software and services,' with hardware and software built in-house — the neocloud pitch of hyperscaler reliability at purpose-built efficiency, and a first-to-deploy record on new NVIDIA silicon. Two things bound the moat, both from the filing: it 'currently rel[ies] on Nvidia for the GPU chips,' the same constraint every neocloud shares, and it is a Nasdaq 'Controlled Company' whose founding shareholder holds concentrated voting power. The three non-core segments (Toloka, Avride, TripleTen) are separate businesses, not the cloud moat. | The textbook answer holds, but not for the textbook reason. Weixin's value is that third parties transact inside it: the report ties Marketing Services growth to closed-loop ads landing in Mini Programs, Mini Shops and Mini Games, ties Business Services growth to 'higher eCommerce technology service fees, underpinned by growth in Mini Shops GMV', and reports that ad load 'remained at a much lower level than peers', so the graph is being monetised deliberately below capacity. On gaming regulation the record is thinner than the received narrative implies: a Hong Kong annual report carries no Risk Factors and no Competition section, and the only place game licensing appears is the Structure Contracts disclosure, where Circular 13 (2009) is discussed as a foreign-ownership question - PRC legal advisers say the arrangement does not violate existing law, while warning of 'substantial uncertainties regarding the interpretation and application' of it. So the disclosed regulatory exposure is structural (VIE legality) rather than an operating constraint on game approvals; the filing simply does not speak to approval throughput at all, and any moat claim resting on it would be unsourced. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| 产业链位置 | Layer-8 neocloud — a purpose-built AI compute provider reselling NVIDIA silicon at scale. | Both a downstream AI deployer and an upstream supplier: the report says Tencent Cloud 'achieved profit at scale due to increased enterprise demand for AI workloads' while AI is also credited with improving its own ad targeting and game content production. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| 产品（份额 / 壁垒） |
|
|
|
| 长周期投票 | -0.01 权重 0.20 · 群体判断 neutral 编辑先验，未经回测。 | +0.42 权重 0.20 · 群体判断 neutral 编辑先验，未经回测。 | -0.17 权重 0.20 · 群体判断 bearish 编辑先验，未经回测。 |